ArticleMolecular biology reports2026
Integrated genetic and clinical investigation of autosomal dominant hereditary uterine leiomyomas: genotype-phenotype correlation in a pakistani family.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary uterine fibroids represent an understudied subset of leiomyomas with limited genetic characterization beyond fumarate hydratase (FH)-associated Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome, where germline heterozygous mutations often cause uterine leiomyomas with cutaneous involvement in many carriers and increased risk of renal cell carcinoma in a minority. AIMS AND
objectivesThis study aimed to identify the genetic basis of isolated autosomal dominant uterine fibroids in a Pakistani family and establish genotype-phenotype correlations through prospective longitudinal phenotyping of proband II-2.
methodsWhole exome sequencing (WES) was performed on proband II-2, followed by multi-step variant filtering and Sanger sequencing validation across all available family members. Structural modeling (MODELLER v10.5), 100-vertebrate conservation analysis, and UCSF Chimera interaction zone analysis complemented functional assessment. Proband II-2 underwent serial ultrasound monitoring from conception through 5.5 months postpartum (~2years).
resultsWES of proband II-2 identified 81,909 raw variants across the exome, which were systematically filtered to yield a single high-confidence heterozygous candidate variant, FH c.568C>T (p.Arg190Cys; ClinVar:141355), previously reported in HLRCC but demonstrating perfect segregation with isolated uterine fibroids across all tested relatives without cutaneous/renal involvement. The variant disrupts an ultra-conserved residue, causing coil-to-β-sheet/α-helix transition, 5 Å zone contraction (15→9 residues), hydrogen bond distortion (2.0 Å→3.0-3.1 Å), and 42.5% residual enzymatic activity in germline heterozygous state, predisposing to two-hit tumorigenesis.. Proband II-2 exhibited dramatic pregnancy-exacerbated growth (76×70 mm at 6w5d → 91×123×87 mm peak at 32w6d), postpartum red/myxoid degeneration, and prolonged menorrhagia.
conclusionWe report heterozygous FH p.Arg190Cys perfectly segregating with the first documented Pakistani pedigree with isolated autosomal dominant uterine leiomyomas without clinically detected HLRCC extra-uterine features, expanding the FH phenotypic spectrum through population-specific expressivity. These findings establish FH screening protocols for familial fibroid cohorts and provide detailed genotype-phenotype correlations for improved clinical management and assessment of fibroids by physicians.
Indexed as
Identifiers
41706343What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.